Veracyte (VCYT) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- S&P 500 ends higher as traders shift from AI to healthcare
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Piper Jaffray Trims PT on Veracyte (VCYT) to $12, Maintains 'Overweight'
August 14, 2015 7:33 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating but trimmed his price target on Veracyte, Inc (NASDAQ: VCYT) to $12.00 (from $13.00) following Q3 results and outook.
Quirk commented, "Veracyte reported a 37.2% yoy revenue increase to $11.9M, above our $11.7M estimate, but below... More



